Android app Apple app link

Novo Nordisk stock slides Monday on second-generation GLP-1 data

By Yahoo! Finance   |   1 month ago
Novo Nordisk stock slides Monday on second-generation GLP-1 data

Novo Nordisk's stock dropped 8% due to disappointing results from the Phase 3 trial of its new GLP-1 drug, CagriSema.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.